The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global vaccine adjuvants market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 12% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Vaccines contain weakened and dead germs that initiate the immune response and activate antigen presenting cells (APCs). This reaction helps the body increase its ability to induce long-term protection and safety against any infection. Vaccine adjuvants are compounds that improve this immunogenic reaction of the body against antigens that have insufficient immunostimulatory capabilities. Aluminum salts and MF59, an oil-in-water emulsion composed of squalene, are among the two common adjuvants that are feasible for human use.
The global vaccine adjuvants market is primarily driven by the rising prevalence of allergies and infectious diseases, including cancer, human immunodeficiency virus (HIV/AIDS), human papillomavirus (HPV) and tuberculosis. The need for advanced treatment options for existing and emerging fatal diseases has resulted in the development of vaccines that have long-lasting effects on immunization. For instance, key manufacturers have developed new adjuvants such as AS01, ISCOM & ISCOMMATRIX, and AS02, which are under clinical trials. Besides this, governments of various countries are taking initiatives for immunization and advancements in adjuvants for human use. They are also focusing on improving healthcare infrastructure and increasing investments for research and development (R&D) of new therapeutics. For example, market players are investing in the development of novel vaccine adjuvants as a potential solution against diseases caused by challenging pathogens, such as malaria and herpes, as well as for vulnerable populations that respond poorly to traditional vaccines, including older adults, neonates, and individuals with compromised immunity and comorbidities. Moreover, with the spread of the coronavirus disease (COVID-19) pandemic caused by SARS-CoV-2, there has been an increasing demand for effective and safe vaccine adjuvants. These factors are expected to provide a positive outlook for the market in the upcoming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine adjuvants market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product type, route of administration, diseases and application.
Breakup by Product Type:
Breakup by Route of Administration:
Breakup by Diseases:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Adjuvance Tecchnologies Inc., Adjuvatis, Agenus Inc., Brenntag SE, Chemtrade Logistics Inc., CSL Limited, Croda International Plc, Invivogen, Novavax Inc., OZ Biosciences and Virometix AG.
|Base Year of the Analysis||2020|
|Segment Coverage||Product Type, Route of Administration, Diseases, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Adjuvance Tecchnologies Inc., Adjuvatis, Agenus Inc., Brenntag SE, Chemtrade Logistics Inc., CSL Limited, Croda International Plc, Invivogen, Novavax Inc., OZ Biosciences and Virometix AG.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at